Angela Webster, MBBS, talks about why only certain patients should be screened for cancer post-transplant.
Obese individuals often are rejected as renal transplant candidates in large part because of their increased risk for surgical complications and adverse outcomes.
Using cephalexin instead of trimethoprim-sulfamethoxazole may decrease UTI incidence and cost of care.
Less than a high school education and delayed graft function are among the factors that increase the risk of readmission within 30 days.
Renal cell carcinoma (RCC) is more likely to develop in male and white patients and those with a history of RCC.
A pre-transplant history of malignancy increases the 10-year post-transplant mortality risk by 22%.
Mean estimated glomerular filtration rate decreases by 0.57 mL/min/1.73 m2 annually with each 1-year increase in age at donation.
In a study, donors were 60% more likely to be diagnosed with gout than matched healthy controls.
They also are at elevated risk of cardiovascular and all-cause mortality, study finds.
No differences found in mortality, CVD between donors, nondonors older than 55.
At last follow-up, 41 of 43 patients who underwent partial nephrectomy did not require dialysis.
Delayed graft function is 41% more likely in obese than non-obese kidney transplant recipients.
Hemodialysis patients are at higher risk than peritoneal dialysis and renal transplant recipients.
When administered concomitantly with tacrolimus in kidney transplant patients, it hiked the risk of acute rejection by more than 2-fold.
Their unadjusted 5-year death-censored graft survival and patient survival rates are higher compared with other recipients.
The odds of receiving a kidney decreased with increasing body mass index.
Lower post-transplant HIV DNA levels associated with sirolimus use.